What We're Reading: Page 141
Industry reads hand-picked by our editors
Nov 11, 2021
Nov 10, 2021
-
The New York Times
Moderna and U.S. at Odds Over Vaccine Patent Rights
-
Reuters
Roche executive says Alzheimer's drug price will be competitive
-
Bloomberg
Canadian Drugmaker Apotex Is Said to Revive Sale Talks
-
The Wall Street Journal
Departing J&J Chief Alex Gorsky Joins Apple’s Board
Nov 09, 2021
-
Science
A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.
-
Bloomberg
Swiss Socialists Want Government to Buy Novartis's Sandoz Unit
-
C&EN
Giving drug researchers control of their data
-
MedPage Today
One Aducanumab Patient, Six Brain Edema Episodes
Nov 08, 2021
Nov 05, 2021
-
The New York Times
He Can’t Cure His Dad. But a Scientist’s Research May Help Everyone Else.
-
The Washington Post
U.S. cancels deal with Emergent BioSolutions, whose plant ruined J&J vaccine doses
-
FiercePharma
Antibody sales boost Regeneron for second straight quarter
-
Healthcare Dive
Women in the healthcare workforce
Nov 04, 2021
-
Reuters
How drugmakers pushed diabetes patients into a danger zone
-
STAT
Ahead of CTAD, Alzheimer's field grapples with new targets and directions
-
Bloomberg
Weight Loss Drug Wegovy of Novo-Nordisk Flies off Shelves
-
Ars Technica
Theranos swiped logos from Pfizer and another pharma giant for fake reports
Nov 03, 2021
-
Wired
The Race Is On to Develop a Vaccine Against Every Coronavirus
-
Evaluate Vantage
Centessa claims a place in the antitrypsin deficiency pipeline
-
Reuters
Lilly pulls COVID-19 treatment from EU review while U.S. stocks up
-
Endpoints News
Bayer backs a George Church spinout trying to turn lab-invented amino acids into a new class of protein therapies
Previous
